颠覆疟疾传播阻断疫苗的范式。
Flipping the paradigm on malaria transmission-blocking vaccines.
作者信息
Dinglasan Rhoel R, Jacobs-Lorena Marcelo
机构信息
Johns Hopkins Malaria Research Institute, Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.
出版信息
Trends Parasitol. 2008 Aug;24(8):364-70. doi: 10.1016/j.pt.2008.05.002. Epub 2008 Jul 1.
Abstract
The idea of malaria transmission-blocking vaccines (TBVs) surfaced more than two decades ago. Since then, the research paradigm focused on developing TBVs that target surface antigens of parasite sexual stages. Only recently has an effort emerged that flipped this paradigm, targeting antigens of the parasite's obligate invertebrate vector, the Anopheles mosquito. Here, we review the current state of knowledge of mosquito-based TBVs and discuss the utility of this approach for future vaccine development.
摘要
疟疾传播阻断疫苗（TBV）的概念在二十多年前就已出现。从那时起，研究范式聚焦于开发针对寄生虫有性阶段表面抗原的TBV。直到最近，才出现了一种转变这一范式的努力，即针对寄生虫专性无脊椎动物载体——按蚊的抗原。在此，我们综述了基于蚊子的TBV的当前知识状态，并讨论了这种方法在未来疫苗开发中的效用。
相似文献
1
Flipping the paradigm on malaria transmission-blocking vaccines.颠覆疟疾传播阻断疫苗的范式。
Trends Parasitol. 2008 Aug;24(8):364-70. doi: 10.1016/j.pt.2008.05.002. Epub 2008 Jul 1.
2
Monoclonal antibody MG96 completely blocks Plasmodium yoelii development in Anopheles stephensi.单克隆抗体MG96可完全阻断约氏疟原虫在斯氏按蚊体内的发育。
Infect Immun. 2003 Dec;71(12):6995-7001. doi: 10.1128/IAI.71.12.6995-7001.2003.
3
Expression, immunogenicity, histopathology, and potency of a mosquito-based malaria transmission-blocking recombinant vaccine.基于蚊子的疟疾传播阻断重组疫苗的表达、免疫原性、组织病理学和效力。
Infect Immun. 2012 Apr;80(4):1606-14. doi: 10.1128/IAI.06212-11. Epub 2012 Feb 6.
4
The Anopheles-midgut APN1 structure reveals a new malaria transmission-blocking vaccine epitope.按蚊中肠APN1结构揭示了一种新的疟疾传播阻断疫苗表位。
Nat Struct Mol Biol. 2015 Jul;22(7):532-9. doi: 10.1038/nsmb.3048. Epub 2015 Jun 15.
5
An analytical review of vector- and pathogen-based transmission-blocking vaccine for malaria control.疟疾防控中基于载体和病原体的阻断传播疫苗的分析性综述。
J Vector Borne Dis. 2022 Jan-Mar;59(1):1-11. doi: 10.4103/0972-9062.318308.
6
The Anopheles innate immune system in the defense against malaria infection.按蚊的先天免疫系统在抵御疟疾感染中的作用。
J Innate Immun. 2014;6(2):169-81. doi: 10.1159/000353602. Epub 2013 Aug 28.
7
Molecular characterization of the carboxypeptidase B1 of Anopheles stephensi and its evaluation as a target for transmission-blocking vaccines.斯氏按蚊羧肽酶 B1 的分子特征及其作为传播阻断疫苗靶标的评估。
Infect Immun. 2013 Jun;81(6):2206-16. doi: 10.1128/IAI.01331-12. Epub 2013 Apr 8.
8
Transmission blocking malaria vaccines: Assays and candidates in clinical development.传播阻断型疟疾疫苗：临床开发中的检测方法与候选疫苗
Vaccine. 2015 Dec 22;33(52):7476-82. doi: 10.1016/j.vaccine.2015.08.073. Epub 2015 Sep 26.
9
Peptide mimics as surrogate immunogens of mosquito midgut carbohydrate malaria transmission blocking targets.肽模拟物作为蚊子中肠碳水化合物疟疾传播阻断靶点的替代免疫原。
Vaccine. 2005 Apr 15;23(21):2717-24. doi: 10.1016/j.vaccine.2004.11.063.
10
Immunopotentiation by Lymph-Node Targeting of a Malaria Transmission-Blocking Nanovaccine.通过淋巴节点靶向疟疾传播阻断纳米疫苗实现免疫增强。
Front Immunol. 2021 Aug 27;12:729086. doi: 10.3389/fimmu.2021.729086. eCollection 2021.
引用本文的文献
1
Evaluation of a new fusion antigen, cd loop and HAP2-GCS1 domain (cd-HAP) of Plasmodium falciparum Generative Cell Specific 1 antigen formulated with various adjuvants, as a transmission blocking vaccine.评估一种新的融合抗原，即恶性疟原虫生殖细胞特异性 1 抗原的 cd 环和 HAP2-GCS1 结构域（cd-HAP），与各种佐剂联合配制，作为一种传播阻断疫苗。
Malar J. 2023 Dec 9;22(1):374. doi: 10.1186/s12936-023-04798-7.
2
Advances in Non-Chemical Tools to Control Poultry Hematophagous Mites.控制家禽吸血螨的非化学工具进展
Vet Sci. 2023 Sep 22;10(10):589. doi: 10.3390/vetsci10100589.
3
vaccine: What is the best way to go?疫苗：哪种途径最好？
Front Immunol. 2023 Jan 16;13:910236. doi: 10.3389/fimmu.2022.910236. eCollection 2022.
4
Are malaria transmission-blocking vaccines acceptable to high burden communities? Results from a mixed methods study in Bo, Sierra Leone.疟疾传播阻断疫苗是否能被高负担社区接受？来自塞拉利昂博城的一项混合方法研究结果。
Malar J. 2021 Apr 13;20(1):183. doi: 10.1186/s12936-021-03723-0.
5
Immunofocusing humoral immunity potentiates the functional efficacy of the AnAPN1 malaria transmission-blocking vaccine antigen.免疫聚焦体液免疫增强了AnAPN1疟疾传播阻断疫苗抗原的功能效力。
NPJ Vaccines. 2021 Apr 6;6(1):49. doi: 10.1038/s41541-021-00309-4.
6
A Hetero-Multimeric Chitinase-Containing and Ookinete-Secreted Protein Complex Involved in Mosquito Midgut Invasion.一种包含异源多聚体几丁质酶的合胞体蛋白复合物，参与蚊子中肠入侵。
Front Cell Infect Microbiol. 2021 Jan 8;10:615343. doi: 10.3389/fcimb.2020.615343. eCollection 2020.
7
Progress towards the development of a vaccine.疫苗研发进展。
Expert Rev Vaccines. 2021 Feb;20(2):97-112. doi: 10.1080/14760584.2021.1880898. Epub 2021 Mar 4.
8
Genetic Markers of Adaptation of Plasmodium falciparum to Transmission by American Vectors Identified in the Genomes of Parasites from Haiti and South America.在海地和南美洲寄生虫的基因组中发现了疟原虫适应美洲传播媒介的遗传标记。
mSphere. 2020 Oct 21;5(5):e00937-20. doi: 10.1128/mSphere.00937-20.
9
Prevention and Control Strategies to Counter Zika Virus, a Special Focus on Intervention Approaches against Vector Mosquitoes-Current Updates.寨卡病毒防控策略，特别关注针对媒介蚊虫的干预方法——最新进展
Front Microbiol. 2018 Feb 8;9:87. doi: 10.3389/fmicb.2018.00087. eCollection 2018.
10
Asymptomatic Plasmodium vivax parasitaemia in the low-transmission setting: the role for a population-based transmission-blocking vaccine for malaria elimination.低传播地区无症状间日疟原虫血症：用于消除疟疾的基于人群的传播阻断疫苗的作用。
Malar J. 2018 Feb 21;17(1):89. doi: 10.1186/s12936-018-2243-3.
本文引用的文献
1
Recent developments in synthetic oligosaccharide-based bacterial vaccines.基于合成寡糖的细菌疫苗的最新进展。
Curr Top Med Chem. 2008;8(2):126-40. doi: 10.2174/156802608783378864.
2
Glycoconjugates in cancer therapy.癌症治疗中的糖缀合物
Anticancer Agents Med Chem. 2008 Jan;8(1):92-121. doi: 10.2174/187152008783330815.
3
Peptide mimotopes as prototypic templates of broad-spectrum surrogates of carbohydrate antigens for cancer vaccination.肽模拟表位作为用于癌症疫苗接种的碳水化合物抗原广谱替代物的原型模板。
Crit Rev Immunol. 2007;27(3):247-70. doi: 10.1615/critrevimmunol.v27.i3.50.
4
Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial.RTS,S/AS02D候选疟疾疫苗在莫桑比克高流行地区婴儿中的安全性：一项双盲随机对照I/IIb期试验
Lancet. 2007 Nov 3;370(9598):1543-51. doi: 10.1016/S0140-6736(07)61542-6. Epub 2007 Oct 18.
5
Immunogenicity in rhesus of the Plasmodium vivax mosquito stage antigen Pvs25H with Alhydrogel and Montanide ISA 720.间日疟原虫蚊期抗原Pvs25H与氢氧化铝佐剂及Montanide ISA 720在恒河猴体内的免疫原性
Parasite Immunol. 2007 Oct;29(10):525-33. doi: 10.1111/j.1365-3024.2007.00971.x.
6
Plasmodium falciparum ookinetes require mosquito midgut chondroitin sulfate proteoglycans for cell invasion.恶性疟原虫动合子侵入细胞需要蚊子中肠硫酸软骨素蛋白聚糖。
Proc Natl Acad Sci U S A. 2007 Oct 2;104(40):15882-7. doi: 10.1073/pnas.0706340104. Epub 2007 Sep 14.
7
The salivary glands and saliva of Anopheles gambiae as an essential step in the Plasmodium life cycle: a global proteomic study.冈比亚按蚊的唾液腺和唾液在疟原虫生命周期中的关键作用：一项全球蛋白质组学研究
Proteomics. 2007 Sep;7(18):3384-94. doi: 10.1002/pmic.200700334.
8
Mosquito stage, transmission blocking vaccines for malaria.疟疾的蚊虫阶段传播阻断疫苗
Curr Opin Infect Dis. 2007 Oct;20(5):476-81. doi: 10.1097/QCO.0b013e3282a95e12.
9
Disruption of Plasmodium falciparum development by antibodies against a conserved mosquito midgut antigen.抗保守蚊虫中肠抗原的抗体对恶性疟原虫发育的干扰。
Proc Natl Acad Sci U S A. 2007 Aug 14;104(33):13461-6. doi: 10.1073/pnas.0702239104. Epub 2007 Aug 2.
10
The surface protein Pvs25 of Plasmodium vivax ookinetes interacts with calreticulin on the midgut apical surface of the malaria vector Anopheles albimanus.间日疟原虫动合子的表面蛋白Pvs25与疟疾媒介白纹按蚊中肠顶端表面的钙网蛋白相互作用。
Mol Biochem Parasitol. 2007 Jun;153(2):167-77. doi: 10.1016/j.molbiopara.2007.03.002. Epub 2007 Mar 12.
Zotero 插件